U.S. FDA APPROVES PFIZER?S XELJANZ (TOFACITINIB) FOR THE TREATMENT OF ACTIVE POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS
September 28, 2020
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ??(tofacitinib) for the treatment of children and adolescents 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA). Two formulations were approved, a tablet and an oral solution, and are dosed based upon weight.1?This approval makes XELJANZ the first and only Janus kinase (JAK) inhibitor approved in the U.S. for the treatment of pcJIA.
?Polyarticular course juvenile idiopathic arthritis, or pcJIA, is debilitating as it can cause significant jointpain and limit participation in child appropriate activities,? said Dr. Hermine Brunner, Director of the Division of Rheumatology at Cincinnati Children?s Hospital Medical Center and Scientific Director of the Pediatric Rheumatology Collaborative Study Group. ?Although there arealready several advanced treatments available, tofacitinib will be an appealing new option given it does not require injectionsor infusions. These can be quite burdensome to both children with pcJIA and their caretakers. The FDA approval of Xeljanz for pcJIA is positive news for this community as it provides a new advanced treatment option in an oral formulation.?2a,2b,3a,4a,5a,5b,5c
This approval was based on data from a Phase 3 study including two phases: an 18-week open-label, run-in phase (including 225 patients), followed by a 26-week double-blind, placebo-controlled, randomized, withdrawal phase (including 173 patients) for a total duration of 44 weeks. The study evaluated the efficacy and safety of tofacitinib taken as either a 5 mg tablet or as a 1 mg/mL oral solution twice daily based on the subject?s body weight (<40 kg for the oral solution) and/or patient preference.6a,6b?The trial met its primary endpoint showing that in patients with pcJIA who achieved a juvenile idiopathic arthritis (JIA) American College of Rheumatology (ACR) 30 response at the end of the run-in phase, the occurrence of disease flare in patients treated with tofacitinib (31 percent; n/N=27/88) was statistically significantly (p=0.0007) lower than patients treated with placebo (55 percent; n/N=47/85) at week 44.6c,6d?In this study, disease flare was defined as a 30 percent or more worsening in at least three of the six variables of the JIA ACR core set, with no more than one of the remaining JIA core response variables improving by 30 percent or more (outcome measures used in JIA clinical trials) after randomization, 6e,7
In general, the types of adverse drug reactions in patients with pcJIA were consistent with those seen in adult rheumatoid arthritis (RA) patients.Please see important safety information below.
?Many children and adolescents living with polyarticular course juvenile idiopathic arthritis, or pcJIA, are in need of advanced oral treatment options, so we are proud to now offer XELJANZ to this patient community,?4a?said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. ?This approval, which is the fourth indication for XELJANZ, reinforces its utility in the treatment of immune-mediated inflammatory conditions and further demonstrates our expertise in JAK science.?
XELJANZ oral solution is anticipated to be available by the end of Q1 2021. XELJANZ 5 mg tablets are available immediately.
About Juvenile Idiopathic Arthritis
Juvenile idiopathic arthritis (JIA) is a chronic inflammatory disease of unknown etiology. JIA includes six categories: systemic, oligoarticular, polyarticular, enthesitis-related, psoriatic, and undifferentiated. Polyarticular JIA is characterized by arthritis in five or more joints and affects both the small joints of the hands and feet, and large joints like the knees, hips and ankles.2a,2b,3a,8a?JIA is defined as arthritis that begins before 16 years of age and persists for at least six weeks.8b?While its cause is unknown, approximately 300,000 children in the U.S. have a form of JIA.9,4b
About XELJANZ??(tofacitinib)
XELJANZ??(tofacitinib) isapproved in the U.S. in four indications: adults with moderately to severely active rheumatoid arthritis (RA) after methotrexate failure, adults with active psoriatic arthritis (PsA) after disease modifying antirheumatic drug (DMARD) failure, adults with moderately to severely active ulcerative colitis (UC) after tumor necrosis factor inhibitor (TNFi) failure, and patients 2 years of age or older with active polyarticular course juvenile idiopathic arthritis (pcJIA). XELJANZ has been studied in more than 50 clinical trials worldwide, including more than 20 trials in RA patients, and prescribed to over 208,000 adult patients (the majority of whom were RA patients) worldwide in the last seven years.?10,11,12
As the developer of tofacitinib, Pfizer is committed to advancing the science of JAK inhibition and enhancing understanding of tofacitinib through robust clinical development programs in the treatment of immune-mediated inflammatory conditions.
INDICATIONS
Rheumatoid Arthritis
- XELJANZ/XELJANZ XR (tofacitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
- Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
- XELJANZ/XELJANZ XR (tofacitinib) is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
- Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
- XELJANZ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or who are intolerant to TNF blockers.
- Limitations of Use: Use of XELJANZ in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
- XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older.
- Limitations of Use: Use of XELJANZ/XELJANZ Oral Solution in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
###
____________________________ 1?XELJANZ Label. September 2020. 2?Oberle EJ, Harris JG, Verbsky JW. Polyarticular juvenile idiopathic arthritis - epidemiology and management approaches. Clin Epidemiol. 2014;6:379-393. Published 2014 Oct 24. doi:10.2147/CLEP.S53168- Page 10/Column 2/Paragraph 4/Lines 7-9
- Page 2/Column 1/Paragraph 2/Lines 6-7
- Page 2/Paragraph 1
- Page 1/Paragraph 1/Lines 1-4
- Page 2/Paragraph 8-13
- Page 1/Treatment
- Page 1/Paragraph 1/Lines 9-11
- Page 13-15/Paragraphs 1-16
- /Page 20/Paragraph 5/Lines1-3
- Page 21/Most Trouble Side Effect of Treatment Graph
- Page 1/Study Design/Paragraph 1
- Page 2/Subject Population/Paragraph 1/Line 1
- Page 4/Efficacy: Key Results & Supportive Findings/Paragraph 1
- Page 1/Protocol Objectives and Endpoints/Paragraph 1
- Page 1/Executive Summary/Paragraph 1/Lines 3-4
Share this article on WhatsApp, LinkedIn and Twitter
X
Incisive News in 3 Shots.
Contact Us
- First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
- +91-120 428 0707
- connect@pharmashots.com
- Newsletter
Our Information
Copyright © 2024 PharmaShots - All Rights Reserved.
Modal title
Modal body text goes here.